ATLASRoyalty Pharma (RPRX) earnings date: Nov 4, 2026
Royalty Pharma (RPRX) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 4, 2026, before the open. Analysts expect EPS of $1.18.
Source: company filings and exchange data · Updated Nov 2, 2026
Royalty Pharma reports on Nov 4, 2026. One email the day before, with ATLAS’s read on Royalty Pharma. You can switch it off at any time.
Alert me before RPRX reportsFree to start. Creating an account takes under a minute.
RPRX earnings at a glance
| Next report (confirmed) | Wed, Nov 4, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | $1.18 |
| Last report | Aug 5, 2026 · Beat |
| Beat rate (last 5 reports) | 5 of 5 (100%) |
| Average EPS surprise | +10.1% |
| Average move around a report | ±1.0% (last 5) |
| Sector | Healthcare · Biotechnology |
Royalty Pharma earnings history: last 5 reports
Royalty Pharma last reported on Aug 5, 2026: EPS of $1.32 against an estimate of $1.27 (+3.9% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 5, 2026 | $1.27 | $1.32 | +3.9% | Beat | -0.4% |
| Jul 27, 2026 | $1.54 | $1.69 | +9.7% | Beat | +1.9% |
| May 6, 2026 | $1.18 | $1.30 | +10.2% | Beat | -0.5% |
| Feb 11, 2026 | $1.33 | $1.47 | +10.5% | Beat | +1.3% |
| Jan 23, 2026 | $1.61 | $1.87 | +16.2% | Beat | +0.9% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
ATLAS view on RPRX before the report
| Last price | $67.18 (+1.9%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 52% |
| Likely 1-month range (50%) | $64.50 – $70.41 |
| Normal 1-day range (±1σ) | ±1.5% |
| ATLAS fair value | $43.88 ($34.78 – $54.80) · price is 53% above |
These figures come from the same calibrated model and valuation as the Royalty Pharma stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Get the full ATLAS analysis for RPRX
See the fair value, the probability range and the earnings history of Royalty Pharma on its ATLAS page.
Royalty Pharma (RPRX) stock analysisPlans from €3.99 a month.
Royalty Pharma earnings: frequently asked questions
When does Royalty Pharma (RPRX) report earnings?
Royalty Pharma is scheduled to report on Wednesday, November 4, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for RPRX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is $1.18 per share (USD). Estimates can change before the report.
How often does RPRX beat earnings estimates?
Of its last 5 reports with a recorded result, Royalty Pharma beat the EPS estimate 5 times; the average surprise was +10.1%. Past results do not predict the next one.
How much does RPRX move around earnings?
Over its last 5 reports the stock moved an average of 1.0% (absolute, from the close before the report day to the close after it), and finished higher 3 of 5 times.
Did Royalty Pharma beat earnings estimates last quarter?
Royalty Pharma last reported on Aug 5, 2026: EPS of $1.32 against an estimate of $1.27 (+3.9% surprise), a beat.
How much does RPRX usually move in a day?
On a normal trading day the ATLAS model puts RPRX’s one-day range at about ±1.5%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 4, 2026
Educational information, not investment advice. Disclaimer